Table 1 Demographic and clinical characteristics of the three groups.
HCs | Asymptomatic LRRK2 Carriers | PD | POST-HOC | POST-HOC | POST-HOC | |
|---|---|---|---|---|---|---|
HCs vs LRRK2 | HCs vs PD | LRRK2 vs PD | ||||
p-value | p-value | p-value | ||||
Age (Years) | 64.4 ± 4.2 | 67.1 ± 4.8 | 64.2 ± 6.4 | 0.098# | 0.856 | 0.087# |
Sex (M/F) | 16/14 | 10/5 | 11/11 | |||
Duration (Years) | – | – | 5.25 ± 4.28 | – | – | – |
MDS-UPDRS I | 2.23 ± 3.15 | 3.33 ± 3.29 | 10.73 ± 7.26 | 0.482 | < 0.001* | < 0.001* |
MDS-UPDRS II | 0.13 ± 0.43 | 0.93 ± 1.87 | 11.82 ± 5.79 | 0.465 | < 0.001* | < 0.001* |
MDS-UPDRS III | 1.53 ± 2.42 | 1.60 ± 2.10 | 30.77 ± 11.38 | 0.975 | < 0.001* | < 0.001* |
MDS-UPDRS IV | – | – | 0.64 ± 1.87 | – | – | – |
H&Y scale | – | – | 2.09 ± 0.65 | – | – | – |
LEDD (mg) | – | – | 524.4 ± 301.2 | – | – | – |
